Canadian Substance Use Costs and Harms (2007–2014) updates and expands upon a landmark study from 2006, The Cost of Substance Abuse in Canada 2002. The update took advantage of more complete data and improved analytic techniques to provide cost estimates across a broad range of substances, including alcohol, tobacco, cannabis, opioids, other central nervous system (CNS) depressants (including benzodiazepines, barbiturates, etc.), cocaine, other CNS stimulants (including amphetamine, methamphetamine and ecstasy) and other substances (including hallucinogens and inhalants). In addition to detailing national estimates by substance, the report also presented data by cost type (i.e., healthcare, lost productivity, criminal justice and other direct costs), province and territory, and year, and provided a detailed description of the methods used.